CNS Drugs

CNS Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of novel anti-cancer drug candidates for the treatment of primary and metastatic brain and central nervous system (CNS) tumors. The company's lead drug candidate, Berubicin, is a blood-brain barrier-penetrating anthracycline currently in a potentially pivotal Phase 2 clinical trial for the treatment of glioblastoma multiforme (GBM). In addition to its neuro-oncology focus, the company is developing WP1244, a novel DNA-binding agent that is significantly more potent than daunorubicin in preclinical models. CNS Pharmaceuticals aims to address the high unmet medical need in brain cancer by leveraging its proprietary portfolio of small molecules designed to bypass the blood-brain barrier.